This website uses cookies. By continuing to access the site you are agreeing to their use. Learn more about cookies.

Select country
  • language Clinigen France
  • language Clinigen Germany
  • About Clinigen
    • About us
    • History
    • Responsible business
    • Operational excellence
    • Our brands
  • Global offices
    • Australia & New Zealand
    • Japan
    • Singapore
    • South Africa
    • United Kingdom
    • United States
  • Careers
    • Careers overview
    • Apply Online
    • Frequently Asked Questions
    • Privacy Notice - Applicants
  • Investors
    • At a Glance
    • Financial Highlights
    • Investment Case
      • Business Model
      • Our Track Record
      • Market Overview
      • Strategy
      • Our Businesses
    • Share Tools
    • Results, Reports and Presentations
    • Quantum Archive
    • Financial Calendar
    • Press Releases
      • Press Releases
      • Regulatory News
      • Email Alerts
    • Shareholder Services
      • AGM
      • Registrar Services
      • Major Shareholders
      • Advisor Contacts
      • Analyst Coverage
    • AIM Rule 26
    • Corporate Governance
      • Corporate Governance Statement
      • Board of Directors
      • Tax Strategy
  • Newsroom
    • Video Library
    • Press Releases
    • Stay In Touch
Clinigen-Logo.png
  • Mission
  • How we can help
    Pharmaceutical & Biotech Companies
    Healthcare Professionals
    Patient Groups
    Patients
  • Medicines & Services
    Commercial Medicines >
    • CARDIOXANE®
    • ETHYOL®
    • FOSCAVIR®
    • SAVENE® (Non US)
    • TOTECT® (US only)
    • Partnering with Clinigen
    Unlicensed Medicines >
    • Policy Development
    • Asset Strategy
    • Early Access
    • Real World Evidence
    • Post-Trial Access
    • Phased Launch and Non-Launch Markets
    • Medicine Shortages
    • Market Withdrawal/ Discontinuations
    • Consulting Services
    Clinical Trial Services >
    • Comparator Sourcing and Ancillary Supply
    • Direct-to-site
    • Demand Driven Labelling & Distribution
    • Investigator Initiated Trials
    • Technical Consultancy

    Cliniport Medicine Finder

    Cliniport medicine finder provides access to 10,000 licensed and unlicensed products.

    About Cliniport
  • Insights
Cliniport medicine finder
About Cliniport
Login
Get in touch
Get in touch
  • Mission
  • How we can help
    How we can help
    • Pharmaceutical & Biotech Companies
    • Healthcare Professionals
    • Patient Groups
    • Patients
  • Medicines & Services
    Medicines & Services
    • Commercial Medicines >
      Commercial Medicines >

      Commercial Medicines >

      • CARDIOXANE®
      • ETHYOL®
      • FOSCAVIR®
      • SAVENE® (Non US)
      • TOTECT® (US only)
      • Partnering with Clinigen
    • Unlicensed Medicines >
      Unlicensed Medicines >

      Unlicensed Medicines >

      • Policy Development
      • Asset Strategy
      • Early Access
      • Real World Evidence
      • Post-Trial Access
      • Phased Launch and Non-Launch Markets
      • Medicine Shortages
      • Market Withdrawal/ Discontinuations
      • Consulting Services
    • Clinical Trial Services >
      Clinical Trial Services >

      Clinical Trial Services >

      • Comparator Sourcing and Ancillary Supply
      • Direct-to-site
      • Demand Driven Labelling & Distribution
      • Investigator Initiated Trials
      • Technical Consultancy
  • Insights
  • About Clinigen
    About Clinigen

    About Clinigen

    • About us
    • History
    • Responsible business
    • Operational excellence
    • Our brands
  • Global offices
    Global offices

    Global offices

    • Australia & New Zealand
    • Japan
    • Singapore
    • South Africa
    • United Kingdom
    • United States
  • Careers
    Careers

    Careers

    • Careers overview
    • Apply Online
    • Frequently Asked Questions
    • Privacy Notice - Applicants
  • Investors
    Investors

    Investors

    • At a Glance
    • Financial Highlights
    • Investment Case
      Investment Case

      Investment Case

      • Business Model
      • Our Track Record
      • Market Overview
      • Strategy
      • Our Businesses
    • Share Tools
    • Results, Reports and Presentations
    • Quantum Archive
    • Financial Calendar
    • Press Releases
      Press Releases

      Press Releases

      • Press Releases
      • Regulatory News
      • Email Alerts
    • Shareholder Services
      Shareholder Services

      Shareholder Services

      • AGM
      • Registrar Services
      • Major Shareholders
      • Advisor Contacts
      • Analyst Coverage
    • AIM Rule 26
    • Corporate Governance
      Corporate Governance

      Corporate Governance

      • Corporate Governance Statement
      • Board of Directors
      • Tax Strategy
  • Newsroom
    Newsroom

    Newsroom

    • Video Library
    • Press Releases
    • Stay In Touch
Cliniport
  • About Cliniport
  • Login
Select Country
  • Clinigen France
  • Clinigen Germany

Press Releases

  • About Clinigen
    • About us
    • History
    • Responsible business
    • Operational excellence
    • Our brands
  • Careers
    • Careers overview
    • Apply Online
    • Frequently Asked Questions
    • Privacy Notice - Applicants
  • Newsroom
    • Video Library
    • Press Releases
    • Stay In Touch
  • 2019
  • 2018
  • 2017
  • 2016
  • Archive
More
Filter by
  • 11 Apr 2019

    Clinigen and GC Pharma sign exclusive licensing agreement for Hunterase (Idursulfase-beta) ICV in Japan
    Related materials
    PDF (328.94KB)
  • 02 Apr 2019

    Clinigen completes acquisition of US rights to Proleukin

    Related materials
    PDF (547.74KB)
  • 26 Mar 2019

    Clinigen’s Foscavir® gains approval for HHV-6 encephalitis in Japan
    Related materials
    PDF (431.39KB)
  • 04 Mar 2019

    Clinigen and Eiger BioPharmaceuticals launch worldwide Managed Access Program for lonafarnib for patients with Progeria and Progeroid Laminopathies
    Related materials
    PDF (293.01KB)
  • 27 Feb 2019

    Half Year Results for the Six Months Ended 31 December 2018
    Related materials
    PDF (1.08MB) Presentation Webcast
  • 22 Feb 2019

    Clinigen granted additional indication for Glycopyrronium Bromide to treat paediatric and adolescent severe hypersalivation
    Related materials
    PDF (198.28KB)
Our global offices
  • Australia & New Zealand
  • Japan
  • Singapore
  • South Africa
  • United Kingdom
  • United States
Site
tools
  • Stay In Touch
  • AE Reporting
  • Medical enquiries
  • Terms of use
  • Cookies
  • Privacy policy
  • UK Gender Pay Gap Report
  • Modern Slavery Statement
  • Access Online
  • Sitemap
  • Consumer Information Obligations
Access cliniport

Cliniport medicine finder provides Healthcare Professionals with safe and secure access to 10,000 licensed and unlicensed products.

Log In About Cliniport
  • Twitter
  • Vimeo
  • Linkedin
© Copyright 2019 Clinigen Group plc. By Emperor